Cellectis (CLLS) Cost of Revenue (2015 - 2023)
Cellectis (CLLS) posted quarterly Cost of Revenue of -$344000.0 for Q4 2023, down 149.86% year-over-year from $690000.0 in Q4 2022, and down 193.73% quarter-over-quarter from $367000.0 in Q3 2023.
Cellectis (CLLS) Cost of Revenue (2015 - 2023) Analysis & Trends
Cellectis' Cost of Revenue history runs 9 years deep, the most recent figure standing at -$344000.0 for Q4 2023.
- In Q4 2023, Cost of Revenue fell 149.86% year-over-year to -$344000.0; the TTM figure through Dec 2023 stood at $412000.0 (down 76.74% YoY), while the FY2023 annual figure was $737000.0, down 58.41% from the prior year.
- Cost of Revenue for Q4 2023 stood at -$344000.0, down from $367000.0 in the prior quarter.
- The five-year high for Cost of Revenue was $18.6 million in Q4 2020, with the low at -$344000.0 in Q4 2023.
- The 5-year median for Cost of Revenue is $752500.0 (2019), against an average of $4.0 million.
- The sharpest annual moves came in 2019 and 2023: Cost of Revenue jumped 685.0% in 2019, then tumbled 149.86% in 2023.
- Cellectis' Cost of Revenue stood at $5.7 million in 2019, then soared by 229.87% to $18.6 million in 2020, then tumbled by 98.7% to $243000.0 in 2021, then soared by 183.95% to $690000.0 in 2022, then sank by 149.86% to -$344000.0 in 2023.
- Business Quant data shows CLLS's Cost of Revenue at -$344000.0 in Q4 2023, $367000.0 in Q3 2023, and $55000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -344,000.00 |
| Dec 31, 2023 | -344,000.00 |
| Sep 30, 2023 | 367,000.00 |
| Sep 30, 2023 | 367,000.00 |
| Jun 30, 2023 | 55,000.00 |
| Jun 30, 2023 | 55,000.00 |
| Mar 31, 2023 | 334,000.00 |
| Mar 31, 2023 | 334,000.00 |
| Dec 31, 2022 | 690,000.00 |
| Dec 31, 2022 | 690,000.00 |
| Sep 30, 2022 | 367,000.00 |
| Sep 30, 2022 | 367,000.00 |
| Jun 30, 2022 | 329,000.00 |
| Jun 30, 2022 | 329,000.00 |
| Mar 31, 2022 | 385,000.00 |
| Mar 31, 2022 | 385,000.00 |
| Dec 31, 2021 | 243,000.00 |
| Dec 31, 2021 | 243,000.00 |
| Sep 30, 2021 | 9.21 Mn |
| Sep 30, 2021 | 9.21 Mn |